These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 37146162)

  • 21. Stability of buffer-free freeze-dried formulations: A feasibility study of a monoclonal antibody at high protein concentrations.
    Garidel P; Pevestorf B; Bahrenburg S
    Eur J Pharm Biopharm; 2015 Nov; 97(Pt A):125-39. PubMed ID: 26455339
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High throughput formulation screening for global aggregation behaviors of three monoclonal antibodies.
    Li Y; Mach H; Blue JT
    J Pharm Sci; 2011 Jun; 100(6):2120-35. PubMed ID: 21491438
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High throughput prediction of the long-term stability of pharmaceutical macromolecules from short-term multi-instrument spectroscopic data.
    Maddux NR; Iyer V; Cheng W; Youssef AM; Joshi SB; Volkin DB; Ralston JP; Winter G; Middaugh CR
    J Pharm Sci; 2014 Mar; 103(3):828-39. PubMed ID: 24421157
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of a folding model and in situ spectroscopic techniques for rational formulation development and stability testing of monoclonal antibody therapeutics.
    Rao G; Iyer V; Kosloski MP; Pisal DS; Shin E; Middaugh CR; Balu-Iyer SV
    J Pharm Sci; 2010 Apr; 99(4):1697-706. PubMed ID: 19798762
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Advancing Therapeutic Protein Discovery and Development through Comprehensive Computational and Biophysical Characterization.
    Gentiluomo L; Svilenov HL; Augustijn D; El Bialy I; Greco ML; Kulakova A; Indrakumar S; Mahapatra S; Morales MM; Pohl C; Roche A; Tosstorff A; Curtis R; Derrick JP; Nørgaard A; Khan TA; Peters GHJ; Pluen A; Rinnan Å; Streicher WW; van der Walle CF; Uddin S; Winter G; Roessner D; Harris P; Frieß W
    Mol Pharm; 2020 Feb; 17(2):426-440. PubMed ID: 31790599
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Temperature-ramped studies on the aggregation, unfolding, and interaction of a therapeutic monoclonal antibody.
    Menzen T; Friess W
    J Pharm Sci; 2014 Feb; 103(2):445-55. PubMed ID: 24382634
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mapping the Aggregation Kinetics of a Therapeutic Antibody Fragment.
    Chakroun N; Hilton D; Ahmad SS; Platt GW; Dalby PA
    Mol Pharm; 2016 Feb; 13(2):307-19. PubMed ID: 26692229
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NMR spectroscopy as a characterization tool enabling biologics formulation development.
    Ma J; Pathirana C; Liu DQ; Miller SA
    J Pharm Biomed Anal; 2023 Jan; 223():115110. PubMed ID: 36308923
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Screening of monoclonal antibody formulations based on high-throughput thermostability and viscosity measurements: design of experiment and statistical analysis.
    He F; Woods CE; Trilisky E; Bower KM; Litowski JR; Kerwin BA; Becker GW; Narhi LO; Razinkov VI
    J Pharm Sci; 2011 Apr; 100(4):1330-40. PubMed ID: 24081468
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Application of Affinity-Capture Self-Interaction Nanoparticle Spectroscopy in Predicting Protein Stability, Especially for Co-Formulated Antibodies.
    Zhou M; Yan Z; Li H; Liu X; Sun P
    Pharm Res; 2021 Apr; 38(4):721-732. PubMed ID: 33754257
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Matching pH values for antibody stabilization and crystallization suggest rationale for accelerated development of biotherapeutic drugs.
    Sjuts H; Schreuder H; Engel CK; Bussemer T; Gokarn Y
    Drug Dev Res; 2020 May; 81(3):329-337. PubMed ID: 31758731
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High Throughput Prediction Approach for Monoclonal Antibody Aggregation at High Concentration.
    Zidar M; Šušterič A; Ravnik M; Kuzman D
    Pharm Res; 2017 Sep; 34(9):1831-1839. PubMed ID: 28593474
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High-throughput biophysical analysis of protein therapeutics to examine interrelationships between aggregate formation and conformational stability.
    Chaudhuri R; Cheng Y; Middaugh CR; Volkin DB
    AAPS J; 2014 Jan; 16(1):48-64. PubMed ID: 24174400
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Application of machine learning to predict monomer retention of therapeutic proteins after long term storage.
    Gentiluomo L; Roessner D; Frieß W
    Int J Pharm; 2020 Mar; 577():119039. PubMed ID: 31953088
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of ionic strength and sugars on the aggregation propensity of monoclonal antibodies: influence of colloidal and conformational stabilities.
    Saito S; Hasegawa J; Kobayashi N; Tomitsuka T; Uchiyama S; Fukui K
    Pharm Res; 2013 May; 30(5):1263-80. PubMed ID: 23319172
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Native-state solubility and transfer free energy as predictive tools for selecting excipients to include in protein formulation development studies.
    Banks DD; Latypov RF; Ketchem RR; Woodard J; Scavezze JL; Siska CC; Razinkov VI
    J Pharm Sci; 2012 Aug; 101(8):2720-32. PubMed ID: 22648863
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Liquid formulations for stabilizing IgMs during physical stress and long-term storage.
    Mueller M; Loh MQ; Tscheliessnig R; Tee DH; Tan E; Bardor M; Jungbauer A
    Pharm Res; 2013 Mar; 30(3):735-50. PubMed ID: 23143394
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biophysical Characterization of Binary Therapeutic Monoclonal Antibody Mixtures.
    Krieg D; Berner C; Winter G; Svilenov HL
    Mol Pharm; 2020 Aug; 17(8):2971-2986. PubMed ID: 32687367
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Conformational implications of an inversed pH-dependent antibody aggregation.
    Perico N; Purtell J; Dillon TM; Ricci MS
    J Pharm Sci; 2009 Sep; 98(9):3031-42. PubMed ID: 18803243
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of Hydrogen Exchange Mass Spectrometry as a Stability-Indicating Method for Formulation Excipient Screening for an IgG4 Monoclonal Antibody.
    Toth RT; Pace SE; Mills BJ; Joshi SB; Esfandiary R; Middaugh CR; Weis DD; Volkin DB
    J Pharm Sci; 2018 Apr; 107(4):1009-1019. PubMed ID: 29269271
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.